Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model01:14

Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A higher...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Individualized Longitudinal ctDNA Monitoring in Melanoma Using Multiplexed USE-PCR.

Molecular diagnosis & therapy·2026
Same author

Laboratory Medicine Approaches for Assessing Delayed Graft Function in Renal Transplant.

The journal of applied laboratory medicine·2026
Same author

Development of a Nomogram to Predict Therapeutic Resistance in Metastatic Melanoma Using Longitudinal ctDNA Kinetics.

Molecular diagnosis & therapy·2026
Same author

Evaluation of turnaround times and performance of in-house ChromaCode high-definition PCR compared to send-out next-generation sequencing in non-small cell lung cancer.

American journal of clinical pathology·2025
Same author

Rigorous validation of machine learning in laboratory medicine: guidance toward quality improvement.

Critical reviews in clinical laboratory sciences·2025
Same author

The Correlation between Plasma Circulating Tumor DNA and Radiographic Tumor Burden.

The Journal of molecular diagnostics : JMD·2024

Related Experiment Video

Updated: Jun 27, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Dynamic pharmacogenetic models in anticoagulation therapy.

Marjorie Bon Homme1, Kristen K Reynolds, Roland Valdes

  • 1Department of Pathology and Laboratory Medicine, University of Louisville, 501 South Floyd Street, MDR-218, Louisville, KY 40202, USA.

Clinics in Laboratory Medicine
|December 9, 2008
PubMed
Summary

This study shows how pharmacogenetics combined with pharmacokinetic and pharmacodynamic principles can optimize drug therapy. A dynamic clinical-support tool using warfarin demonstrates improved personalized therapeutics.

Related Experiment Videos

Last Updated: Jun 27, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Area of Science:

  • Pharmacology
  • Genetics
  • Clinical Therapeutics

Background:

  • Individualized drug therapy remains a challenge.
  • Optimizing drug efficacy and safety requires integrating patient-specific factors.
  • Pharmacogenetics offers insights into drug response variability.

Purpose of the Study:

  • To demonstrate a dynamic clinical-support tool for guiding individualized drug therapy.
  • To utilize warfarin as a model for personalized therapeutic optimization.
  • To integrate pharmacogenetics with pharmacokinetic and pharmacodynamic principles.

Main Methods:

  • Development of a dynamic clinical-support tool.
  • Application of pharmacogenetic data.
  • Incorporation of pharmacokinetic and pharmacodynamic principles.
  • Modeling with the drug warfarin.

Main Results:

  • The clinical-support tool effectively guides individualized drug therapy.
  • Integration of pharmacogenetics enhances therapeutic optimization.
  • Warfarin therapy was used as a successful model.

Conclusions:

  • Pharmacogenetics combined with pharmacokinetic and pharmacodynamic principles provides a powerful decision-support tool.
  • This approach optimizes personalized therapeutics.
  • Dynamic clinical-support tools are valuable for precision medicine.